Immunovant (IMVT) reported a fiscal Q2 net loss Monday of $0.73 per diluted share, narrower than the net loss of $0.74 a year earlier.

Analysts polled by FactSet expected a loss of $0.69.

As of Sept. 30, the company said it had $521.9 million in cash and cash equivalents, which will likely finance operations through Graves' disease trial readout anticipated in 2027.